Abstract
Adequate vitamin D status is essential for skeletal health. Paget’s disease of bone (PDB) is a common metabolic skeletal disorder, but data regarding the vitamin D status in PDB patients are lacking. We performed a case–control study to estimate vitamin D status in 708 PDB patients and in 1803 healthy controls from Italy and an observational prospective study to evaluate the efficacy–safety profile of oral cholecalciferol treatment [400.000 International Units (UI) of cholecalciferol administered in cycles of 8 weeks until 25OHD levels reaches 70 nmol/L as primary therapy and 50.000 UI of cholecalciferol administered every 2 weeks for 52 weeks for the maintenance therapy] in 82 PDB patients with hypovitaminosis D, i.e., 25OHD < 50 nmol/L. The main outcome measures for the prospective study were 25OHD levels, metabolic risk factors (RF) for nephrolithiasis, bone pain score (BPS), and pain medication score (PMS). Over half of PDB patients had hypovitaminosis D. Among PDB patients treated with cholecalciferol, 76 patients reached 25OHD levels ≥ 70 nmol/L after the first cycle of primary therapy and the remaining six patients after a second cycle. The maintenance therapy guaranteed 25OHD levels ≥ 70 nmol/L during the entire follow-up. The increase in 25OHD levels reduced PTH, BPS, and PMS levels, without changes in RF for nephrolithiasis. We can conclude that (i) hypovitaminosis D is frequent in PDB patients, (ii) cholecalciferol significantly increased 25OHD levels in PDB patients, and (iii) the correction of hypovitaminosis D improves the quality of life of PDB patients without inducing significant changes in RF for nephrolithiasis.
Similar content being viewed by others
References
Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281
Francis RM, Aspray TJ, Bowring CE, Fraser WD, Gittoes NJ, Javaid MK, Macdonald HM, Patel S, Selby PL, Tanna N (2015) National osteoporosis society practical clinical guideline on vitamin D and bone health. Maturitas 80:119–121
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930
Ralston SH (2013) Clinical practice. Paget’s disease of bone. N Engl J Med 368:644–650
Gennari L, Rendina D, Falchetti A, Merlotti D. Paget’s disease of bone. Calcif Tissue Int in press
Seitz S, Priemel M, von Domarus C, Beil FT, Barvencik F, Amling M, Rueger JM (2008) The second most common bone disease: a review on Paget’s disease of bone. Eur J Trauma Emerg Surg 34:549–553
Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Ralston S (2013) Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone 55:347–352
van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471
Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G (2006) Evidence for increased clinical severity of familial and sporadic Paget’s disease of bone in Campania, southern Italy. J Bone Miner Res 21:1828–1835
Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget’s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 21:P94–P98
Gennari L, Gianfrancesco F, Di Stefano M, Rendina D, Merlotti D, Esposito T, Gallone S, Fusco P, Rainero I, Fenoglio P, Mancini M, Martini G, Bergui S, De Filippo G, Isaia G, Strazzullo P, Nuti R, Mossetti G (2010) SQSTM1 gene analysis and gene-environment interaction in Paget’s disease of bone. J Bone Miner Res 25:1375–1384
Fillée C, Keller T, Mourad M, Brinkmann T, Ketelslegers JM (2012) Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol 76:785–789
Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, Nuti R, Strazzullo P, Mossetti G, Gennari L (2010) FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 163:165–172
Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154
Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC; Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734
Kaye AD, Cornett EM, Hart B, Patil S, Pham A, Spalitta M, Mancuso KF (2018) Novel pharmacological nonopioid therapies in chronic pain. Curr Pain Headache Rep 22:31
Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases. Final results of the study by the radiation therapy oncology group. Cancer 50:893–899
Rendina D, De Filippo G, Postiglione L, Covelli B, Ricciardone M, Guillaume S, Di Spigna G, Selleri C, Merlotti D, Bianciardi S, Materozzi M, Muscariello R, De Pascale F, DʼElia L, Nuti R, Strazzullo P, Gennari L (2018) Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. Pain 159:1664–1673
Tiselius HG (2013) A proposed method for approximate estimates of the ion-activity products of calcium oxalate and calcium phosphate in spot-urine samples or in urine samples collected during less well defined periods of time. Urolithiasis 41:105–109
Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115:2598–2608
Rubenstein L, Robbins A, Josephson K, Schulman B, Osterweil D (1990) The value of assessing falls in an elderly population: a randomised clinical trial. Ann Intern Med 113:308–316
Conley D, Schultz AA, Selvin R (1999) The challenge of predicting patients at risk for falling: development of the Conley Scale. Medsurg Nurs 8:348–354
Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, Guadagno V, Strazzullo P, Nunziata V (2004) Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology 64:833–838
Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737–1744
Thomas L (1997) Retrospective power analysis. Conserv Biol 11:276–280
Battista C, Guarnieri V, Carnevale V, Baorda F, Pileri M, Garrubba M, Salcuni AS, Chiodini I, Minisola S, Romagnoli E, Eller-Vainicher C, Santini SA, Parisi S, Frusciante V, Fontana A, Copetti M, Hendy GN, Scillitani A, Cole DE (2017) Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine 55:266–272
Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V (2004) Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int 75:189–196
Gennari L, Merlotti D, Mossetti G, Rendina D, De Paola V, Martini G, Nuti R (2009) The use of intravenous aminobisphosphonates for the treatment of Paget’s disease of bone. Mini Rev Med Chem 9:1052–1063
Griz L, Bandeira F, Diniz ET, Cabral M, Freese E (2013) Prevalence of vitamin D deficiency is higher in patients with Paget’s disease of bone compared with age-matched controls. Arq Bras Endocrinol Metabol 57:509–512
de Deuxchaisnes CN, Rombouts-Lindemans C, Huaux JP, Devogelaer JP, Withofs H, Meersseman F (1981) Relative vitamin D deficiency in Paget’s disease. Lancet 1:833–834
Guillard-Cumming DF, Beard DJ, Douglas DL, Johnson SK, Lawson-Matthew PJ, Russell RG, Kanis JA (1985) Abnormal vitamin D metabolism in Paget’s disease of bone. Clin Endocrinol (Oxf) 22:559–566
Foldes J, Shamir S, Kidroni G, Menczel J (1989) Vitamin D in Paget’s disease of bone. Clin Orthop Relat Res 243:275–279
Nunziata V, Giannattasio R, di Giovanni G, Lettera AM, Nunziata CA (1993) Vitamin D status in Paget’s bone disease. Effects of calcitonin therapy. Clin Orthop Relat Res 293:366–371
Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor CL (2012) IOM committee members respond to endocrine society vitamin D guideline. J Clin Endocrinol Metab 97:1146–1152
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 97:1153–1158
Bettica P, Bevilacqua M, Vago T, Norbiato G (1999) High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporos Int 9:226–229
Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582
Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch BR, Bianchi M, Stepan J, El-Hajj Fuleihan G, Bouillon R. MANAGEMENT OF ENDOCRINE DISEASE: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. Eur J Endocrinol. in press
Close GL, Leckey J, Patterson M, Bradley W, Owens DJ, Fraser WD, Morton JP (2013) The effects of vitamin D(3) supplementation on serum total 25[OH]D concentration and physical performance: a randomised dose-response study. Br J Sports Med 47:692–696
Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, Sidhom G, Rousseau D, Cole DE, Vieth R (2011) The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation. J Steroid Biochem Mol Biol 126:72–77
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, Siris ES; Endocrine Society (2014) Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:4408–4422
Mossetti G, Vuotto P, Rendina D, Numis FG, Viceconti R, Giordano F, Cioffi M, Scopacasa F, Nunziata V (2003) Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis. J Intern Med 253:194–200
Rendina D, De Filippo G, Gianfrancesco F, Muscariello R, Schiano di Cola M, Strazzullo P, Esposito T (2017) Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers. J Nephrol 30:411–418
Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C (2014) Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 10:007470
Brandi ML, Falchetti A (2006) What is the relationship between Paget’s disease of bone and hyperparathyroidism? J Bone Miner Res 21:P69–P74
Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822
Sanders KM, Nicholson GC, Ebeling PR (2013) Is high dose vitamin D harmful? Calcif Tissue Int 92:191–206
Mackenzie L, Byles J, D’Este C (2006) Validation of self-reported fall events in intervention studies. Clin Rehabil 20:331–339
Funding
This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
Author information
Authors and Affiliations
Contributions
DR designed the study and prepared the first draft of the paper. He is guarantor. GDF, DM, MDS, MS, SMM, SB, EC, RF, RN, PS, and LG contributed to the experimental work. LD’E was responsible for statistical analysis of the data.
Corresponding author
Ethics declarations
Conflict of interest
Domenico Rendina, Gianpaolo De Filippo, Daniela Merlotti, Marco Di Stefano, Mariangela Succoio, Simona Maria Muggianu, Simone Bianciardi, Lanfranco D’Elia, Eleonora Coppo, Raffaella Faraonio, Ranuccio Nuti, Pasquale Strazzullo, and Luigi Gennari declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Ethical Approval
All procedures performed in this study, which involves human participants, were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Human and Animal Rights and Informed Consent
Written informed consent has been obtained from each patient or subject after full explanation of the purpose and nature of all used procedures. The study protocol was approved by the Federico II University Ethical Committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rendina, D., De Filippo, G., Merlotti, D. et al. Vitamin D Status in Paget Disease of Bone and Efficacy–Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D. Calcif Tissue Int 105, 412–422 (2019). https://doi.org/10.1007/s00223-019-00578-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-019-00578-1